000			nab a22 7a 4500
999			_c16902 _d16902
003			PC16902
005			20220615115002.0
008			220615b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91223 _aOrtiz Romero, Pablo Luis _eDermatología Médico-Quirúrgica y Venereología
100			_91219 _aRodríguez Peralto, José Luis _eAnatomía Patológica
245	0	0	_aCutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. _h[artículo]
260			_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology, _c2015
300			_a33(32):3766-73.
500			_aFormato Vancouver: Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015 Nov 10;33(32):3766-73.
501			_aPMID: 26438120 PMC4979132
504			_aContiene 27 referencias
520			_aPurpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients.
710			_9330 _aServicio de Anatomía Patológica
710			_9145 _aServicio de Dermatología Médico-Quirúrgica y Venereología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16902.pdf _ySolicitar documento
942			_2ddc _cART _n0